Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort

CPX-351 is a liposomal formulation of cytarabine and daunorubicin approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). We retrospectively analyzed the efficacy and safety of CPX-351 in a real-w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Chiche, Edmond, Rahmé, Ramy, Bertoli, Sarah, Dumas, Pierre-Yves, Micol, Jean-Baptiste, Hicheri, Yosr, Pasquier, Florence, Peterlin, Pierre, Chevallier, Patrice, Thomas, Xavier, Loschi, Michael, Genthon, Alexis, Legrand, Ollivier, Mohty, Mohamad, Raffoux, Emmanuel, Auberger, Patrick, Caulier, Alexis, Joris, Magalie, Bonmati, Caroline, Roth-Guepin, Gabrielle, Lejeune, Caroline, Pigneux, Arnaud, Vey, Norbert, Recher, Christian, Ades, Lionel, Cluzeau, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7805314/
https://ncbi.nlm.nih.gov/pubmed/33570629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003159
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados